Black Hawk Acquisition Corp
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Emerging growth company
Business Address
4125 BLACKHAWK PLAZA CIRCLE, DANVILLE, CA, 94506
Mailing Address
4125 BLACKHAWK PLAZA CIRCLE, DANVILLE, CA, 94506
Phone
203-520-7122
Fiscal Year End
1130
EIN
000000000
Financial Overview
FY2025
$1.92M
Net Income
$72.14M
Total Assets
$3.90M
Total Liabilities
-$2.17M
Stockholders' Equity
-
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 10-K Annual financial report | March 6, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 13, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 12, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 10, 2025 | View on SEC |
| 10-Q Quarterly financial report | October 21, 2025 | View on SEC |
Annual Reports
10-K
March 6, 2026
- BHAC announced a definitive agreement to merge with Vesicor Therapeutics, Inc., a clinical-stage biotechnology company developing novel gene therapies.
- BHAC successfully completed its IPO in March 2024, raising $69 million, with $69.345 million placed into a trust account.
Material Events
8-K
Financial Distress
April 1, 2026
High Impact
- Company remains in good standing while working toward compliance
- Trading of units, common stock, and rights continues uninterrupted
8-K
Leadership Change
March 17, 2026
High Impact
- Dr. Michael Tolentino appointed CEO of Vesicor Therapeutics, effective March 17, 2026, strengthening leadership for the Black Hawk merger.
- Former CEO Luo Feng transitions to Chief Scientific Officer (CSO), allowing focused expertise on scientific innovation.
Related Companies
Companies in the same industry (SIC: 2836)
Scinai Immunotherapeutics Ltd.
SCNI
Biological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
GNTA
Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd
GRML
Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc.
KYMR
Biological Products, (No Diagnostic Substances)
Innate Pharma SA
IPHA
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.